Skip to main content
. Author manuscript; available in PMC: 2021 Jul 21.
Published in final edited form as: Breast Cancer Res Treat. 2020 Sep 13;185(1):1–12. doi: 10.1007/s10549-020-05917-7

Table 1.

Characteristics of 85 patients with triple-negative breast cancer who received neoadjuvant systemic therapy

Characteristic Study population pCR Non-pCR
No. of patients 85 37/85 (44) 48/85 (56)
Age (years)
Mean ± SD 51.8 ± 13 54.3 ± 13.8 49.9 ± 12.39
Median (range) 51 (26–78) 57 (27–78) 47 (26–75)
Longest tumor diameter (cm)
Mean ± SD 4.57 ± 2.9 3.6 ± 2.18 5.3 ± 3.3
Median (range) 3.8 (1.3–9.8) 3 (1.3–4.4) 4.25 (1.6–9.8)
Tumor histological type
IDC grade II 10/85 (12) 2/37 (5) 8/48 (17)
IDC grade III 72/85 (85) 35/37 (95) 37/48 (77)
Metaplastic 3/85 (3) 0/37 (0) 3/48 (6)
Necrotic tumor histological type
IDC grade II 5/85 (6) 1/37 (3) 4/48 (8)
IDC grade III 32/85 (38) 16/37 (43) 16/48 (33)
Metaplastic 2/85 (2) 0/37 (0) 2/48 (4)
Tumor classification on DCE imaging
Non-necrotic (solid) 46/85 (54) 20/37 (54) 26/48 (54)
Necrotic 39/85 (46) 17/37 (46) 22/48 (46)
Type of surgery
Total mastectomy 47/85 (55) 21/37 (57) 28/48 (58)
Conservative surgery 38/85 (45) 16/37 (43) 20/48 (42)

Data are number of patients (percent) unless otherwise indicated

DCE dynamic contrast-enhanced, IDC infiltrating ductal carcinoma, pCR pathological complete response, SD standard deviation, TNBC triple-negative breast cancer